Wegovy vs Zepbound: The Two FDA-Approved Obesity Meds Compared (2026)

The short answer

Wegovy is semaglutide 2.4 mg, a GLP-1 receptor agonist from Novo Nordisk. Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist from Eli Lilly. Both are FDA-approved for chronic weight management in adults with obesity or overweight with weight-related conditions. Both are once-weekly subcutaneous injections. Zepbound produces more weight loss on average; Wegovy has more cardiovascular outcomes evidence. The choice between them often comes down to insurance coverage, cash-pay pricing, and specific clinical context.

Head-to-head trial numbers

The pivotal obesity trials for each drug used similar designs but different populations and follow-up windows:

• Wegovy (semaglutide 2.4 mg), STEP 1 trial: 1,961 adults with obesity, 68 weeks. Mean weight loss on semaglutide 2.4 mg: approximately 14.9% of body weight vs 2.4% on placebo. About 86% of participants lost at least 5% of body weight.
• Zepbound (tirzepatide), SURMOUNT-1 trial: 2,539 adults with obesity, 72 weeks. Mean weight loss on tirzepatide 15 mg: approximately 20.9% of body weight vs 3.1% on placebo. About 96% of participants lost at least 5% of body weight.

The direct head-to-head trial that eventually settled the class question was SURMOUNT-5, which compared tirzepatide and semaglutide directly in obesity. Tirzepatide produced significantly more weight loss than semaglutide across dose comparisons.

Practical translation: for a patient starting at 220 lb (100 kg), Wegovy would be expected to produce ~33 lb loss on average; Zepbound would be expected to produce ~46 lb loss. Individual results vary enormously; roughly a third of patients on either drug are "super-responders" who lose substantially more than average.

Mechanism differences

Wegovy activates one receptor. Zepbound activates two.

Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, the gut hormone that signals satiety, slows gastric emptying, and triggers glucose-dependent insulin release. The downstream effects on appetite, food intake, and glycemic control drive the weight loss.

Zepbound (tirzepatide) is a dual agonist. Along with GLP-1 receptor agonism, it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone with related but distinct metabolic effects. The additional GIP activity appears to contribute to greater weight loss and possibly modulates side effects.

The mechanistic difference matters clinically. Adding GIP agonism to GLP-1 agonism produces more weight loss than either alone. Whether that GIP contribution comes primarily through additional appetite suppression, effects on adipose tissue, or through interaction with GLP-1 signaling is still being characterized. The MariTide program (Amgen) is specifically testing whether GIP antagonism (the opposite direction) might produce even better outcomes, complicating the mechanistic picture.

Cardiovascular evidence: where Wegovy pulls ahead

Wegovy has a substantial cardiovascular outcomes trial completed. Zepbound's is still running.

Wegovy, SELECT trial (Lincoff et al., NEJM 2023): 17,604 adults aged 45+ with established cardiovascular disease and overweight or obesity (but without diabetes). Wegovy reduced the primary composite cardiovascular endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) by 20% compared with placebo over a mean follow-up of about 3 years. This established cardiovascular protection beyond weight loss.

Zepbound, SURMOUNT-MMO trial: Ongoing. Enrolling patients with obesity and cardiovascular disease to test whether tirzepatide provides similar cardiovascular protection. Results expected 2027-2028.

For patients with established cardiovascular disease, Wegovy currently has the stronger evidence base. This is a meaningful clinical distinction. Some cardiologists specifically prefer Wegovy in this population because of the completed CVOT.

Side-effect profiles

Both drugs share the standard incretin class side-effect pattern: gastrointestinal symptoms during titration that generally improve over time.

Nausea is the most common side effect on both. Around 44% of Wegovy users report nausea in STEP 1; around 25-33% report nausea across Zepbound dose arms in SURMOUNT-1. Zepbound may have slightly lower nausea rates at comparable weight-loss magnitudes, though the difference is not dramatic.

Vomiting, diarrhea, and constipation occur at meaningful rates on both drugs during dose escalation. These typically attenuate after the first 4-8 weeks at a given dose.

Injection site reactions are mild and infrequent on both.

Gallbladder events occur at rates above placebo for both drugs. Rapid weight loss itself increases gallbladder disease risk; the drugs may add additional risk beyond that.

Pancreatitis is a known class effect at very low rates. Users with prior pancreatitis history should discuss the specific risk with their prescriber.

Thyroid C-cell tumors appeared in rodent studies for the class. There is a boxed warning on both products. Human evidence for meaningful thyroid cancer risk is not compelling but the FDA required labeling.

Hair shedding is a documented but often-missed side effect. See our GLP-1 hair loss article for the mechanism (rapid weight loss triggers telogen effluvium) and mitigation approaches.

Facial volume loss ("Ozempic face") can occur with either drug when weight loss is substantial and rapid. See our Ozempic face article for the biology and prevention strategies.

Muscle loss during rapid weight loss on either drug is a real concern. See our avoiding muscle loss article for the evidence and mitigation framework.

Dosing and titration

Both drugs use gradual dose escalation over months to improve tolerability.

Wegovy dose escalation: Start at 0.25 mg weekly, then escalate monthly through 0.5 mg, 1.0 mg, 1.7 mg, and up to the 2.4 mg maintenance dose over 16 weeks. Some patients tolerate the escalation better than others; slower titration can help patients struggling with side effects.

Zepbound dose escalation: Start at 2.5 mg weekly, escalate monthly by 2.5 mg increments through 5 mg, 7.5 mg, 10 mg, 12.5 mg, up to the 15 mg maximum dose. The maintenance dose for optimal weight loss is often 10-15 mg; some patients respond well at lower doses.

Both drugs use auto-injector pens; the delivery mechanics are similar. Zepbound is also available as a vial format through LillyDirect for cash-pay patients (see below).

Cost and coverage in 2026

List prices are similar for both drugs: approximately $1,000-1,300 per month at wholesale acquisition cost. What patients actually pay depends on coverage.

Commercial insurance with coverage: Typically $25-100/month copay if the plan covers obesity medications. Many plans require prior authorization or step therapy (trying cheaper alternatives first).

Manufacturer savings programs: Both drugs have savings cards for commercially-insured patients. Novo Nordisk offers programs for Wegovy; Lilly offers programs for Zepbound. Eligible commercially-insured patients typically pay $25-150/month with the savings card.

Cash-pay without insurance:

• Zepbound: LillyDirect offers Zepbound vials (not pens) at $349-499/month depending on dose. This is currently the cheapest brand-name access route without insurance.
• Wegovy: Novo Nordisk's NovoCare direct-to-patient program has more limited cash-pay options; pricing structure is different and generally less consumer-friendly than LillyDirect.

Medicare: Coverage for obesity medications by Medicare has been limited historically but expanded through 2024-2026. Coverage varies by plan and specific clinical criteria.

Medicaid: Coverage varies substantially by state.

For patients without insurance coverage of obesity medications, the LillyDirect cash-pay pathway for Zepbound often makes it the more accessible option even though Wegovy has some cheaper insurance-covered scenarios.

Which one is "better"?

The framing depends on what "better" means for a specific patient.

Better for maximum weight loss: Zepbound. Head-to-head trial data (SURMOUNT-5) confirmed tirzepatide produces more weight loss than semaglutide.

Better for established cardiovascular disease: Wegovy, based on the completed SELECT cardiovascular outcomes trial. Zepbound's cardiovascular trial is ongoing.

Better for kidney disease: Wegovy currently has more evidence in patients with kidney disease from the FLOW trial in diabetic kidney disease.

Better for tolerability: Roughly similar; Zepbound may have slightly less nausea at comparable weight loss.

Better for cash-pay access: Zepbound via LillyDirect.

Better for insurance coverage: Depends entirely on your specific plan.

Better for MASH (fatty liver disease): Both work; Zepbound has emerging evidence, Wegovy has some evidence, direct comparison not yet available.

Better for sleep apnea: Zepbound has FDA approval for obstructive sleep apnea with obesity based on SURMOUNT-OSA trial. Wegovy does not currently have this indication.

Switching between them

Patients sometimes switch from Wegovy to Zepbound (or occasionally the other direction). The clinical mechanics are straightforward but the practical considerations matter.

Switching Wegovy → Zepbound: no direct dose equivalent, but a rough starting point is Zepbound 5 mg weekly for a patient who was on Wegovy 1.7 or 2.4 mg. Titrate up from there based on tolerability and response. Expect to lose more weight on Zepbound.

Switching Zepbound → Wegovy: less common but sometimes done for cardiovascular-evidence reasons or coverage reasons. Rough starting point is Wegovy 1.0 or 1.7 mg for patients on Zepbound 5-10 mg, escalating to 2.4 mg maintenance.

Common reasons to switch: insurance coverage changes, side effect issues, plateau on the current drug, desire for the specific evidence base of the other drug, or physician preference change.

The most important practical point: switching doesn't restart the weight-loss curve from zero. Your weight typically continues along the trajectory you were on, just adjusted for the different drug's efficacy magnitude.

What to discuss with your prescriber

• Your current cardiovascular risk profile and history (informs the Wegovy CVOT-evidence angle)
• Your kidney function (informs specific evidence considerations)
• Whether you have obstructive sleep apnea (Zepbound now has that FDA indication)
• Your insurance coverage of both drugs
• Cash-pay options if coverage is limited (Zepbound LillyDirect vs Wegovy NovoCare)
• Your side-effect history with GLP-1 medications if any
• Your weight-loss goals and how much weight loss magnitude matters vs other factors
• Your upcoming surgical procedures (both drugs require preoperative pause, see our drug interactions article)

Related reading

For the broader class comparison, see our Semaglutide vs Tirzepatide article. For the brand-name landscape, see our Semaglutide brand names explainer (Ozempic, Wegovy, Rybelsus) and Mounjaro vs Zepbound (same molecule, different brand names). For the pipeline of next-generation candidates that may eventually compete with both drugs, see our GLP-1 pipeline 2026 and beyond coverage and the Retatrutide, MariTide, and CagriSema peptide pages.